Acquires royalty interests in biopharmaceutical products, focusing on monetizing intellectual property.
Royalty Pharma plc functions as a prominent player in the biopharmaceutical industry, specializing in acquiring biopharmaceutical royalties and funding innovations within the sector across the United States. The company's core operations include identifying, evaluating, and acquiring royalties associated with a diverse array of biopharmaceutical therapies. Royalty Pharma plc collaborates extensively with innovators spanning academic institutions, research hospitals, not-for-profits, as well as small and mid-cap biotechnology and pharmaceutical companies.
Central to Royalty Pharma plc's business model is its robust portfolio, encompassing royalties on approximately 35 marketed therapies and 10 developmental-stage product candidates. These therapies cover a broad spectrum of therapeutic areas including rare diseases, oncology, neurology, infectious diseases, hematology, and diabetes. By strategically acquiring and managing these royalties, the company plays a vital role in supporting ongoing research and development efforts aimed at advancing medical treatments globally.
Founded in 1996 and headquartered in New York, New York, Royalty Pharma plc has established itself as a key financial partner within the biopharmaceutical ecosystem. With a track record of successful collaborations and investments, the company continues to drive innovation and contribute to advancements in healthcare through its unique approach to royalty acquisition and funding.